Ibrutinib targets the B-cell receptor pathway and immune cells in the tumor microenvironment via BTK, as well as kinases relevant to solid tumor treatment [8,9,10], including tyrosine kinase ETK/BMX [11] and interleukin-2–inducible T-cell kinase (ITK) [12]. This evidence concerns the gene ITK and neoplasm.